Nolvadex (Tamoxifen Citrate)

Nolvadex should be used with caution in patients with persistent leukopenia and thrombocytopenia. Periodic checks are recommended haematological, piastrinemia included. You can verify shutdown of menstrual flow in Premenopausal patients, which does not affect the anticancer activity of the drug. During treatment with Nolvadex has been reported an increased incidence of endometrial abnormalities including polyps, hyperplasia, carcinoma and sarcoma of the body of the uterus (usually malignant mixed mullerian derivatives). The incidence and the framework of these changes suggest a basic mechanism related to properties estrogeniche of Nolvadex. It is advisable, therefore, that the patients undergoing therapy to be subject to appropriate supervision of genital organs, in particular the endometrium. Patients being treated with tamoxifen should be instructed to notify their physician immediately if they experience any of the following symptoms: numbness of the face or weakness in the arms or legs and speech problems or vision that might indicate a stroke cerebri. Same in case of chest pain or breathlessness which might be symptoms of pulmonary embolism or if you have abdominal pain or abnormal vaginal bleeding that might indicate a possible cancer of the uterus. Even in the case of cough and dyspnea that may be symptoms of Interstitial pneumonia patients should be instructed to notify your doctor. Must be applied to patients if they have had a previous history of stroke cerebri, events similar to the stroke, thromboembolic events or cancer of the uterus. Patients should be informed of the need to avoid pregnancy during treatment with Nolvadex and, if sexually active, should use barrier contraceptives or other non-hormonal contraceptive methods. The patients in pre-menopause, before starting the treatment, must be subjected to careful controls to exclude the possibility of pregnancy. Patients should be informed of potential risks to the fetus if a pregnant herself during treatment with Nolvadex or within two months after discontinuation of therapy. Breastfeeding: the use of Nolvadex during lactation is not recommended, as it is not known whether it is excreted into breast milk. The decision to discontinue breast-feeding or treatment with Nolvadex should be evaluated according to the need for treatment.